Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives
Maria Pia Paroli,Emanuela Del Giudice,Francesca Giovannetti,Rosalba Caccavale,Marino Paroli
DOI: https://doi.org/10.2147/OPTH.S342717
2022-05-29
Clinical Ophthalmology
Abstract:Maria Pia Paroli, 1 Emanuela Del Giudice, 2 Francesca Giovannetti, 1 Rosalba Caccavale, 3 Marino Paroli 3 1 Uveitis Service, Ophthalmologic Unit, Department of Sense Organs, Sapienza University of Rome, Rome, Italy; 2 Pediatric Rheumatology Unit, Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy; 3 Clinical Immunology Unit, Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy Correspondence: Maria Pia Paroli, Uveitis Service, Ophthalmologic Unit, Department of Sense Organs, Sapienza University of Rome, Rome, Italy, Tel/Fax +39-06-519-3220, Email Juvenile idiopathic arthritis (JIA) is the most common extraocular disease associated with pediatric uveitis. Despite the growing knowledge about the pathogenetic and clinical characteristics of the disease, it still remains a challenge for both the pediatric rheumatologist and ophthalmologist. Since uveitis is asymptomatic in most cases, it is generally detected by parents in a late phase of the disease when complications have occurred with consequent severe vision loss. Improvement in attentive screening and early treatment initiation to suppress inflammation has considerably reduced the sight-threatening outcomes of JIA-associated chronic anterior uveitis (JIA-CAU). Initial treatment with topical steroids is effective in most cases. However, more severe cases require the use of periocular or systemic corticosteroids, possibly leading to long-term complications. These include growth retardation, cataract and glaucoma. Systemic immunosuppressive agents are then employed in patients resistant to first-line therapy or to reduce steroid-associated complications. In this review, we will discuss the immunosuppressant agents currently employed for the treatment of the disease, including anti-tumor necrosis factor (TNF)α biologics approved or not by the regulatory agencies. We will also highlight how new therapeutic options like biologic targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) co-stimulatory molecule, interleukin-6 receptor (IL-6R) or B lymphocytes might represent exciting new options for patients resistant to conventional therapy. Finally, the potential use of janus kinase (JAK) inhibitors recently approved for the treatment of several inflammatory rheumatic diseases in adults will be also discussed. Keywords: juvenile idiopathic arthritis, uveitis, biologics, JAK inhibitors Juvenile idiopathic arthritis (JIA) is a progressive rheumatic disease characterized by chronic joint inflammation of unknown etiology. 1 The condition begins typically before the age of 16 and lasts at least six weeks. JIA global prevalence is about 1:1000. 2 Epidemiological studies have shown that the disease occurs more frequently in certain areas including North America, Scandinavia, United Kingdom and Germany. 3 Based on the course of the disease, the International League of Associations of Rheumatology (ILAR) has recognized 7 subtypes: 4 a) systemic JIA; b) oligoarthritis; c) rheumatoid factor (RF)-negative polyarthritis; d) RF-positive polyarthritis; e) psoriatic arthritis (PsA); f) enthesitis-related arthritis (ERA); g) undifferentiated arthritis (UA). JIA is by far the systemic disease most frequently associated with anterior uveitis in the pediatric population, accounting for up to 47% of all types of uveitis seen in children. 3,5 With regard to the different subtypes, it has been reported that about 20% of patients affected by oligoarticular JIA and 10% by RF-negative polyarticular JIA are affected by CAU. In addition, ERA and PsA subtypes have been found to be at high risk of acute and recurrent forms of uveitis. In the remaining JIA subtypes uveitis is rare. 1 Both eyes may be affected within the first year of JIA, but in these cases ocular inflammation is often asymptomatic, 6–8 while uveitis precedes arthritis in only 3–7% of cases. 9 Patients with antinuclear antibody (ANA)-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. One-third of ANA-positive, early-onset JIA patients develop CAU within the first 5 years of the disease. 10 A number of risk factors for developing uveitis by JIA patients have been identified. These include: female gender, the oligoarticular form, early onset, ANA positivity, presence of HLA-DRB1*11 or HLA-DRB1*13 and RF-negative test. 11 Since the disease is asymptomatic in most cases, it can be detected by parents only when complications such as band keratopathy or strabismus occur or by failed vision screening. Thus, slit-lamp screening is mandatory to prevent sight-threatening complications, -Abstract Truncated-